C

Clinilabs Drug Development Corporation | Eatontown, NJ

Research site

Location

4 Industrial Way West 2nd Floor, Eatontown, New Jersey, United States of America

Site insights

Top conditions

Top treatments

INZ-701

ANC-501

GATE-101

Aroxybutynin

IXT-m200

OXY

Psilocybin Analog

Atomoxetine

ALA-3000

venlafaxine XR

Parent organization

This site is a part of Clinilabs Drug Development Corporation

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

3 of 16 total trials

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Defici...

Enrolling

Arterial Calcification

Autosomal Recessive Hypophosphatemic Rickets Type 2

Drug: INZ-701

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent...

Enrolling

Friedreich Ataxia

Drug: CTI-1601

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine